Staidson Biopharmaceuticals has supported a $34m series C round for InflaRx, which is working on treatments for acute and chronic inflammatory conditions.

Germany-based biopharmaceutical company InflaRx has raised €31m ($34m) in a series C round that included drug developer Staidson Biopharmaceuticals, which contributed through its corporate venturing subsidiary Staidson Hong Kong Investment.

Unnamed family offices, industrial investors and existing equity holders also took part in the round.

InflaRx is working on therapies to tackle a range of acute and chronic inflammatory conditions. Its lead drug candidate, IFX-1, successfully completed a phase 2a clinical trial in January 2016 for patients suffering from early…